Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 11/20 | 0.37 |
| ▸ | CCR3 | P51677 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208925 | 0.93 | CYP2C9 (0.62) | CYP2C9KCNH2WDR5HRH3CXCR3 | |
| SCHEMBL2206302 | 0.91 | CYP2C9 (0.63) | CYP2C9KCNH2WDR5CXCR3CCR3 | |
| SCHEMBL2208676 | 0.91 | CYP2C9 (0.60) | CYP2C9KCNH2WDR5 | |
| SCHEMBL1376452 | 0.89 | CYP2C9 (0.73) | CYP2C9KCNH2WDR5HRH3 | |
| SCHEMBL1378080 | 0.88 | CYP2C9 (0.77) | CYP2C9KCNH2WDR5HRH3 | |
| SCHEMBL2207925 | 0.86 | CYP2C9 (0.55) | CYP2C9KCNH2WDR5 | |
| SCHEMBL2208600 | 0.85 | CYP2C9 (0.80) | CYP2C9KCNH2HRH3CXCR3 | |
| SCHEMBL2205295 | 0.85 | CYP2C9 (0.59) | CYP2C9KCNH2WDR5 | |
| SCHEMBL2206768 | 0.83 | CYP2C9 (0.62) | CYP2C9KCNH2WDR5CXCR3 | |
| SCHEMBL1379153 | 0.81 | CYP2C9 (0.76) | CYP2C9KCNH2WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | SUMMA VINCENZO | 2011-10-20 | — | — | US | claimed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | claimed |
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | SUMMA VINCENZO | 2011-10-20 | — | — | US | disclosed |
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | SUMMA VINCENZO | 2011-10-20 | — | — | US | disclosed |
| US-7981879-B2 | HIV integrase inhibitors | Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2011-07-19 | — | — | US | disclosed |
| US-7981879-B2 | HIV integrase inhibitors | Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2011-07-19 | — | — | US | disclosed |
| US-7981879-B2 | HIV integrase inhibitors | Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2011-07-19 | — | — | US | disclosed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | disclosed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | disclosed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | REV1, CDK9, INTS9 | CYP2C9 672/4885KCNH2 2918/4885WDR5 2157/4885 |
| US-20090253681-A1 | HIV Integrase Inhibitors | REV1, INTS9, H1-10 | CYP2C9 449/4885KCNH2 3625/4885WDR5 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.